LIFEMD INC (LFMD)

US53216B1044 - Common Stock

5.75  +0.52 (+9.94%)

After market: 5.8 +0.05 (+0.87%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LFMD. LFMD was compared to 37 industry peers in the Health Care Technology industry. Both the profitability and financial health of LFMD have multiple concerns. LFMD shows excellent growth, but is valued quite expensive already.



Quickly go to:

2

1. Profitability

1.1 Basic Checks

LFMD had negative earnings in the past year.
LFMD had a positive operating cash flow in the past year.
In the past 5 years LFMD always reported negative net income.
In multiple years LFMD reported negative operating cash flow during the last 5 years.

1.2 Ratios

LFMD has a worse Return On Assets (-35.30%) than 60.00% of its industry peers.
Industry RankSector Rank
ROA -35.3%
ROE N/A
ROIC N/A
ROA(3y)-117.88%
ROA(5y)-183.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of LFMD (89.64%) is better than 94.29% of its industry peers.
In the last couple of years the Gross Margin of LFMD has grown nicely.
The Profit Margin and Operating Margin are not available for LFMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.79%
GM growth 5Y2.59%

More info and screens

2

2. Health

2.1 Basic Checks

LFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LFMD has been increased compared to 1 year ago.
Compared to 5 years ago, LFMD has more shares outstanding
Compared to 1 year ago, LFMD has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.08, we must say that LFMD is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.08, LFMD is doing worse than 62.86% of the companies in the same industry.
LFMD has a debt to FCF ratio of 1.72. This is a very positive value and a sign of high solvency as it would only need 1.72 years to pay back of all of its debts.
LFMD's Debt to FCF ratio of 1.72 is fine compared to the rest of the industry. LFMD outperforms 74.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.72
Altman-Z -1.08
ROIC/WACCN/A
WACC9.93%

2.3 Liquidity

A Current Ratio of 0.83 indicates that LFMD may have some problems paying its short term obligations.
LFMD has a worse Current ratio (0.83) than 77.14% of its industry peers.
LFMD has a Quick Ratio of 0.83. This is a bad value and indicates that LFMD is not financially healthy enough and could expect problems in meeting its short term obligations.
LFMD's Quick ratio of 0.78 is on the low side compared to the rest of the industry. LFMD is outperformed by 77.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.78

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.69% over the past year.
LFMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.15%.
Measured over the past years, LFMD shows a very strong growth in Revenue. The Revenue has been growing by 79.00% on average per year.
EPS 1Y (TTM)34.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)42.15%
Revenue growth 3Y59.92%
Revenue growth 5Y79%
Sales Q2Q%38.28%

3.2 Future

The Earnings Per Share is expected to grow by 32.61% on average over the next years. This is a very strong growth
Based on estimates for the next years, LFMD will show a very strong growth in Revenue. The Revenue will grow by 28.23% on average per year.
EPS Next Y19.44%
EPS Next 2Y39.35%
EPS Next 3Y31.7%
EPS Next 5Y32.61%
Revenue Next Year38.86%
Revenue Next 2Y31.68%
Revenue Next 3Y26.42%
Revenue Next 5Y28.23%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LFMD. In the last year negative earnings were reported.
Also next year LFMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, LFMD is valued a bit cheaper than the industry average as 77.14% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 23.3
EV/EBITDA N/A

4.3 Compensation for Growth

LFMD's earnings are expected to grow with 31.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.35%
EPS Next 3Y31.7%

More info and screens

0

5. Dividend

5.1 Amount

LFMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFEMD INC

NASDAQ:LFMD (1/3/2025, 8:00:02 PM)

After market: 5.8 +0.05 (+0.87%)

5.75

+0.52 (+9.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners38.56%
Inst Owner Change6.85%
Ins Owners17.06%
Ins Owner Change3.68%
Market Cap247.65M
Analysts81.33
Price Target12.24 (112.87%)
Short Float %16.4%
Short Ratio8.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP-12.13%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.34%
Min EPS beat(2)-49.02%
Max EPS beat(2)-15.66%
EPS beat(4)1
Avg EPS beat(4)-17.42%
Min EPS beat(4)-49.02%
Max EPS beat(4)15.97%
EPS beat(8)2
Avg EPS beat(8)-40.52%
EPS beat(12)3
Avg EPS beat(12)-33.85%
EPS beat(16)5
Avg EPS beat(16)-81.42%
Revenue beat(2)1
Avg Revenue beat(2)0.12%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)2.94%
Revenue beat(4)3
Avg Revenue beat(4)2.65%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)8.61%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)5
Avg Revenue beat(12)-2.02%
Revenue beat(16)5
Avg Revenue beat(16)-2.35%
PT rev (1m)-5.62%
PT rev (3m)-4.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-183.81%
EPS NY rev (1m)-1.13%
EPS NY rev (3m)-5.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.18%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.28
P/FCF 23.3
P/OCF 11.44
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0.25
FCFY4.29%
OCF(TTM)0.5
OCFY8.74%
SpS4.48
BVpS-0.18
TBVpS-0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.3%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.64%
FCFM 5.51%
ROA(3y)-117.88%
ROA(5y)-183.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.79%
GM growth 5Y2.59%
F-Score6
Asset Turnover2.66
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.72
Debt/EBITDA N/A
Cap/Depr 124.1%
Cap/Sales 5.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.78
Altman-Z -1.08
F-Score6
WACC9.93%
ROIC/WACCN/A
Cap/Depr(3y)251.46%
Cap/Depr(5y)170.88%
Cap/Sales(3y)5.58%
Cap/Sales(5y)3.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y19.44%
EPS Next 2Y39.35%
EPS Next 3Y31.7%
EPS Next 5Y32.61%
Revenue 1Y (TTM)42.15%
Revenue growth 3Y59.92%
Revenue growth 5Y79%
Sales Q2Q%38.28%
Revenue Next Year38.86%
Revenue Next 2Y31.68%
Revenue Next 3Y26.42%
Revenue Next 5Y28.23%
EBIT growth 1Y-37.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year187.06%
EBIT Next 3Y67.65%
EBIT Next 5Y59.57%
FCF growth 1Y129.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y180.8%
OCF growth 3YN/A
OCF growth 5YN/A